Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-4-19
pubmed:abstractText
PURPOSE Few data are available on breast cancer characteristics, treatment, and survival for women age 80 years or older. PATIENTS AND METHODS We used the linked Surveillance, Epidemiology and End Results-Medicare data set from 1992 to 2003 to examine tumor characteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy or alone, or no surgery), and outcomes of women age 80 years or older (80 to 84, 85 to 89, > or = 90 years) with stage I/II breast cancer compared with younger women (age 67 to 79 years). We used Cox proportional hazard models to examine the impact of age on breast cancer-related and other causes of death. Analyses were performed within stage, adjusted for tumor and sociodemographic characteristics, treatments received, and comorbidities. Results In total, 49,616 women age 67 years or older with stage I/II disease were included. Tumor characteristics (grade, hormone receptivity) were similar across age groups. Treatment with BCS alone increased with age, especially after age 80. The risk of dying from breast cancer increased with age, significantly after age 80. For stage I disease, the adjusted hazard ratio of dying from breast cancer for women age > or = 90 years compared with women age 67 to 69 years was 2.6 (range, 2.0 to 3.4). Types of treatments received were significantly associated with age and comorbidity, with age as the stronger predictor (26% of women age > or = 80 years without comorbidity received BCS alone or no surgery compared with 6% of women age 67 to 79 years). CONCLUSION Women age > or = 80 years have breast cancer characteristics similar to those of younger women yet receive less aggressive treatment and experience higher mortality from early-stage breast cancer. Future studies should focus on identifying tumor and patient characteristics to help target treatments to the oldest women most likely to benefit.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-10091795, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-10749910, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-10931455, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-11400963, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-11550141, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-12039930, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-12913099, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-15342804, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-15342805, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-15681522, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-1632698, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-16705122, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-16779876, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-16782915, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-16782916, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-16983106, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-17004115, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-17043276, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-17593042, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-18155570, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-18428196, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-19451448, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-20308651, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-2334566, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-3763482, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-4058507, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-8637025, http://linkedlifedata.com/resource/pubmed/commentcorrection/20308658-9750244
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2038-45
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed-meshheading:20308658-Age Factors, pubmed-meshheading:20308658-Aged, pubmed-meshheading:20308658-Aged, 80 and over, pubmed-meshheading:20308658-Antineoplastic Agents, pubmed-meshheading:20308658-Breast Neoplasms, pubmed-meshheading:20308658-Chemotherapy, Adjuvant, pubmed-meshheading:20308658-Comorbidity, pubmed-meshheading:20308658-Female, pubmed-meshheading:20308658-Health Services for the Aged, pubmed-meshheading:20308658-Healthcare Disparities, pubmed-meshheading:20308658-Humans, pubmed-meshheading:20308658-Logistic Models, pubmed-meshheading:20308658-Mastectomy, pubmed-meshheading:20308658-Mastectomy, Segmental, pubmed-meshheading:20308658-Neoplasm Staging, pubmed-meshheading:20308658-Patient Selection, pubmed-meshheading:20308658-Physician's Practice Patterns, pubmed-meshheading:20308658-Proportional Hazards Models, pubmed-meshheading:20308658-Radiotherapy, Adjuvant, pubmed-meshheading:20308658-Registries, pubmed-meshheading:20308658-Risk Assessment, pubmed-meshheading:20308658-Risk Factors, pubmed-meshheading:20308658-SEER Program, pubmed-meshheading:20308658-Time Factors, pubmed-meshheading:20308658-Treatment Outcome, pubmed-meshheading:20308658-United States
pubmed:year
2010
pubmed:articleTitle
Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival.
pubmed:affiliation
Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446, USA. mschonbe@bidmc.harvard.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural